



RESULTS OF THE THIRD QUARTER, 2018

- RESULTS OF THE EUROPEAN FET-OPEN "CALL ON PROJECTS"

- A NEW RESEARCH PROJECT WITH THE UNIVERSITY OF MONTPELLIER, FRANCE

Arles, October 24, 2018 - CELL CONSTRAINT & CANCER, a company specializing in the treatment of pancreatic cancer by mechanical signals, presents its review of the past period, as well as its strategic priorities for the next quarter.

RESULTS OF THE FET-OPEN CALL

CC & C participated, within the NanoStress consortium gathered around the INSERM research laboratory of Alain Couvineau (Bichat Hospital, Paris) in the May 2018 session of the call for projects Future Emerging Technologies (FET-Open) launched by the European Commission to emerging breakthrough innovations on the European continent.

We have received the answer: unfortunately, it is negative. Our file has received a score of 4.0 / 5 when the score of 4.5 was needed to be funded. So, we got pretty close. This is why all members of the consortium decided to resubmit an improved file for the next session on January 24, 2019.

The result of this new submission will be known in April / May, with work starting in September / October. We need to learn from the comments of the reviewers. Among the positive points:

- our scientific bases are solid,
- our device is very innovative, and can potentially have a very important impact on how to treat cancer and save many lives,
- finally, the team gathered within the consortium is coherent, complementary and of a very high level.

All this is warm to the heart, but the critics of the reviewers are obviously what we are going to focus on to rewrite our dossier. First of all, we have to fix some problems of clarity and rigor in writing. Above all, there is a need to improve project management: better define the objectives, milestones, control tools, to anticipate delays and obstacles and provide solutions. Finally, the reviewers asked us to be more specific about how we see the transfer of our technology to industry.

OTHER PARTNERSHIPS: UNIVERSITY OF MONTPELLIER, STANFORD AND IBDM

Our strategy remains the same: to associate with public research laboratories and launch partnership research projects to obtain the Proof of Efficacy. It is in this context that we begin a collaboration with the IMNO laboratory of Charles Gerhardt Institute of Montpellier (icgm.fr) and the Structural Biology Center of Montpellier (cbs.cnrs.fr). Discussions are ongoing, but this basic research experiment should focus on the behavior of one or a few pancreatic cells, subjected to a stress field. Remember that so far, Physical Oncology almost did not focus on the pancreas or pancreatic tumors. So, this is an important issue for us. The partnership with Stanford University's Laboratory of Physical Oncology was paused pending the results of the FET-Open. We must now restart discussions with our correspondent and reactivate this contact.

Moreover, the experimentation at the IBDM is going on; timeline is respected. The applications for funding are submitted, the project leader, Elsa Bazellières, announces that she hired an engineer and a student dedicated to the project, and the first organoids were put into cultivation. The aim of the experiment is to check the action of mechanical signals on an organoid of colon tumor cells ([see our Press Release of 20](#)

[September 2018](#) for more details). The first results are expected for the very beginning of 2019 and will give way to a more ambitious experiment.

Other partnerships need to be put in place to build other grant files. The ideas of experimentation do not miss, the field to be cleared is vast and potential partners are numerous in France, in Europe and all over the world.

INCREASE IN STAFF AND CAPITAL INCREASE

To cope with this increase in research activity, we will need to hire a full-time researcher to help our Scientific Director, Rémy Brossel, to set up and follow experiments. This is the challenge of the year 2019. The financing requirement is of the order of 60,000 Euros. The current capital increase will raise a first part of this amount by the end of the year. The search for investors like Business Angels, or industrial partners is ongoing.

Next appointment: December 31, 2018 - Update on Q4 2018 activity

Find all the information on CELL CONSTRAINT & CANCER:

<http://new.cellconstraintcancer.com/>



About CELL CONSTRAINT & CANCER

Founded in 2009 by Rémy BROSSSEL, medical oncologist and physicist, CELL CONSTRAINT & CANCER develops innovative treatments based on [physical oncology](#), complementary to current approaches to oncology. Addressing primarily non-metastatic non-operable tumors, such as cancer of the pancreas, brain, or liver, the company published in May 2016 a proof of concept of slowing the growth of an in vivo grafted cancer tumor, by the action of mechanical signals (read our article: [Mechanical signals inhibit growth of a grafted tumor in vivo: Proof of Concept](#)).

The establishment of major partnerships (CNRS, INSERM, Stanford University) and the support of its shareholders since its beginning allow today to initiate a new phase of experiments on animals intended to provide proof of the efficacy of this technology on unmet medical needs.

CONTACTS

Press Relations
Barthélémy BROSSSEL
Tél. : +33 (0)6 50 22 79 64
Mail : barth.brossel@gmail.com

Shareholders & Investors Relations
Christine GRAU
Tél. : +33 (0)4 90 18 48 50
Mail : investisseurs@cellconstraintcancer.com